Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Market Cap	1.55T +44.2%
Revenue (ttm)	139.80B +21.4%
Net Income	21.63B +13.2%
EPS	63.92 +13.2%
Shares Out	n/a
PE Ratio	71.57
Forward PE	63.28
Dividend	38.00 (0.83%)
Ex-Dividend Date	May 29, 2026

Volume	425,984
Open	4,619.50
Previous Close	4,572.20
Day's Range	4,557.90 - 4,666.00
52-Week Range	3,140.10 - 4,712.90
Beta	0.15
Analysts	Buy
Price Target	4,878.79 (+6.73%)
Earnings Date	May 22, 2026

About Torrent Pharmaceuticals

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Employees: 18,258
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: TORNTPHARM

Financial Performance

In fiscal year 2026, Torrent Pharmaceuticals's revenue was 139.80 billion, an increase of 21.39% compared to the previous year's 115.16 billion. Earnings were 21.63 billion, an increase of 13.19%.

Analyst Summary

According to 28 analysts, the average rating for TORNTPHARM stock is "Buy." The 12-month stock price target is ₹4,879, which is an increase of 6.73% from the latest price.

Price Target

₹4,879

(6.73% upside)

Analyst Consensus: Buy